No photo of Catherine S Perry

View Scopus Profile

Catherine S Perry

  • 5478 Citations
  • 35 h-Index
1984 …2018

Research output per year

If you made any changes in Pure these will be visible here soon.

Fingerprint Dive into the research topics where Catherine S Perry is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 3 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output

  • 5478 Citations
  • 35 h-Index
  • 78 Article
  • 2 Letter
  • 1 Review article

Continued excellent outcomes in previously untreated patients with follicular lymphoma after treatment with CHOP plus rituximab or CHOP plus 131I-Tositumomab: Long-Term follow-up of phase III randomized study SWOG-S0016

Shadman, M., Li, H., Rimsza, L., Leonard, J. P., Kaminski, M. S., Braziel, R. M., Spier, C. M., Gopal, A. K., Maloney, D. G., Cheson, B. D., Dakhil, S., LeBlanc, M., Smith, S. M., Fisher, R. I., Friedberg, J. W. & Press, O. W., Mar 1 2018, In : Journal of Clinical Oncology. 36, 7, p. 697-703 7 p.

Research output: Contribution to journal › Article

    • 22 Scopus citations

    Impact of histological grading on survival in the SWOG S0016 follicular lymphoma cohort

    Rimsza, L. M., Li, H., Braziel, R. M., Perry, C. S., Persky, D. O., Dunlap, J., Leblanc, M., Bartlett, N., Leonard, J. P., Smith, S. M., Press, O. W. & Friedberg, J. W., Mar 23 2018, In : Haematologica. 103, 4, p. e151-e153

    Research output: Contribution to journal › Letter

    4 Scopus citations

    Phase I Study of the Investigational Aurora A Kinase Inhibitor Alisertib plus Rituximab or Rituximab/Vincristine in Relapsed/Refractory Aggressive B-cell Lymphoma

    Kelly, K. R., Friedberg, J. W., Park, S. I., McDonagh, K., Hayslip, J., Persky, D., Ruan, J., Puvvada, S. D., Rosen, P., Iyer, S. P., Stefanovic, A., Bernstein, S. H., Weitman, S., Karnad, A., Monohan, G., VanderWalde, A., Mena, R., Schmelz, M., Perry, C. S., Groshen, S. & 5 others, Venkatakrishnan, K., Zhou, X., Sheldon-Waniga, E., Jane Leonard, E. & Mahadevan, D., Dec 15 2018, In : Clinical Cancer Research. 24, 24, p. 6150-6159 10 p.

    Research output: Contribution to journal › Article

    • 8 Scopus citations

    Co-targeting aurora kinase with PD-L1 and PI3K abrogates immune checkpoint mediated proliferation in peripheral T-cell lymphoma: A novel therapeutic strategy

    Islam, S., Vick, E., Huber, B., Morales, C., Spier, C., Cooke, L., Weterings, E. & Mahadevan, D., Jan 1 2017, In : Oncotarget. 8, 59, p. 100326-100338 13 p.

    Research output: Contribution to journal › Article

    • 7 Scopus citations

    Disruption of aneuploidy and senescence induced by aurora inhibition promotes intrinsic apoptosis in double hit or double expressor diffuse large B-cell lymphomas

    Islam, S., Qi, W., Morales, C., Cooke, L., Spier, C., Weterings, E. & Mahadevan, D., Oct 2017, In : Molecular Cancer Therapeutics. 16, 10, p. 2083-2093 11 p.

    Research output: Contribution to journal › Article

    • 11 Scopus citations